A complete absence of cannabinoid receptors in a living human has never been documented, and based on what we know from genetics and animal research, it almost certainly isn’t compatible with normal health. These receptors are so deeply wired into basic brain and immune function that losing them entirely would cause serious problems. However, people absolutely can have fewer receptors than normal, or receptors that don’t work as well, due to genetic variation, lifestyle factors, or chronic conditions.
What Cannabinoid Receptors Actually Do
Your body has two main types of cannabinoid receptors, called CB1 and CB2, and they handle very different jobs. CB1 receptors are concentrated in the brain and nervous system, where they act as a braking mechanism for nerve signaling. When a nerve cell fires too much, the receiving cell produces its own cannabis-like chemicals (endocannabinoids) that travel backward across the gap between neurons and land on CB1 receptors on the sending cell, telling it to quiet down. This “retrograde signaling” is the primary way your endocannabinoid system regulates everything from pain perception and anxiety to motor control and reward.
CB2 receptors are found mainly in immune cells. B cells (which produce antibodies) express the highest amounts, followed by natural killer cells, macrophages, and T cells. CB2 is the main receptor through which the endocannabinoid system tunes immune responses, helping calibrate inflammation up or down as needed.
Together, these two receptor types form a signaling network that touches nearly every major system in the body. They’ve been around for a very long time evolutionarily. CB1 and CB2 genes appear in all vertebrates, from zebrafish to birds to mammals, and a shared ancestor receptor has been found even in sea squirts, placing the origin of this system at over 500 million years ago. That kind of deep evolutionary conservation is a strong signal that these receptors aren’t optional equipment.
What Happens When Both Receptors Are Missing
The closest thing to a total absence of cannabinoid receptors exists in lab mice that have been genetically engineered to lack both CB1 and CB2. These “double knockout” mice are born alive and appear healthy for the first couple of months. But around eight weeks of age, things go wrong. In a study published in Epilepsia, 80% of double-knockout mice monitored with continuous brain recordings developed epilepsy, experiencing spontaneous seizures. About 28% had seizures triggered simply by being handled during routine cage changes. And 22% of the double-knockout mice in the study died prematurely before experiments could even begin.
The seizures were severe, often involving full-body convulsions with rearing and falling. In some cases, a single seizure was fatal. One mouse had a 76-second seizure and died immediately afterward. Critically, mice missing only CB1 or only CB2 did not develop seizures at all, suggesting the two receptor types can partially compensate for each other. It’s only when both are gone that the system collapses.
This makes biological sense. Without CB1 receptors acting as brakes on nerve signaling, neurons can fire unchecked, creating the kind of runaway electrical activity that produces seizures. Without CB2 receptors moderating immune function, inflammation goes unregulated. The double-knockout mice demonstrate that a complete absence of cannabinoid receptors is survivable at birth but progressively dangerous.
Genetic Variation in Humans
No human has been found with both cannabinoid receptor genes completely knocked out. But people do carry rare mutations that alter how well these receptors function. A study of over 6,000 patients with neurological disorders identified 22 people carrying rare coding variants in the CB1 receptor gene (CNR1) and 11 with variants in the CB2 gene (CNR2). The CB1 variants were significantly associated with increased pain sensitivity, particularly migraine, along with sleep problems and memory difficulties, sometimes combined with anxiety.
These aren’t cases of missing receptors entirely. They’re cases where the receptor protein is slightly different from normal, potentially less efficient or expressed at lower levels. Even these partial changes in CB1 function produced measurable neurological effects. Variants in the CB2 gene, interestingly, were not linked to any neurological symptoms in the same study, which aligns with CB2’s primary role in immune tissue rather than the brain.
Reduced Receptors From Lifestyle and Environment
Even without genetic mutations, your cannabinoid receptor levels aren’t fixed. They shift in response to what you do. The most well-documented example is chronic cannabis use. PET brain imaging of daily cannabis smokers has shown clear downregulation of CB1 receptors, meaning the brain reduces the number of available receptors in response to being constantly flooded with external cannabinoids. The reduction was most pronounced in the cortex, the brain’s outer layer responsible for higher-order thinking, and correlated with how many years a person had been smoking.
The good news from that research: after about four weeks of monitored abstinence, CB1 receptor density returned to normal levels. The downregulation was fully reversible. This tells us something important about the system’s resilience. Your body actively manages receptor levels, dialing them up or down based on demand, but it doesn’t eliminate them.
Clinical Endocannabinoid Deficiency
A related concept that gets discussed in medical literature is clinical endocannabinoid deficiency, or CECD. First proposed by neurologist Ethan Russo, this theory suggests that some people produce too few endocannabinoids or have too few functioning receptors, creating a state of system-wide underactivity rather than total absence. The conditions linked to this proposed deficiency include migraine, fibromyalgia, and irritable bowel syndrome, all of which share features like heightened pain sensitivity, disrupted sleep, and treatment resistance.
CECD remains a hypothesis rather than an established diagnosis. There’s no standard clinical test for it. But the pattern it describes, a spectrum of endocannabinoid system activity ranging from robust to deficient, fits what the genetic and imaging research shows. Some people’s systems simply run at lower capacity than others.
Why a Total Absence Is Essentially Impossible
The CNR1 and CNR2 genes that encode cannabinoid receptors are present in every human genome. For someone to completely lack both receptors, they would need to inherit two nonfunctional copies of both genes, one from each parent, for both receptor types simultaneously. Given how essential these receptors are to brain stability and immune regulation, such a combination would likely cause severe problems early in development or infancy, similar to what the double-knockout mice experience but potentially worse, since human brains are far more complex.
What does exist, and what most people asking this question are probably sensing, is a wide range of receptor density and efficiency across the population. You can have significantly fewer or less responsive cannabinoid receptors due to genetics, chronic substance use, stress, or illness. That functional reduction can produce real symptoms. But “fewer” and “none” are very different things, and the biology makes clear that zero is not a number the human body can work with.